Author: Editor

Shaji K. Kumar, MD of Mayo Clinic

Shaji K. Kumar, MD of Mayo Clinic gives an overview of the upcoming treatment trends for multiple myeloma, which include combination therapy after relapse, longer duration of treatment, early intervention, and clinical trials development. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Shaji K. Kumar, MD of Mayo Clinic discusses how to gain a better understanding in treating multiple myeloma. He states that most patients who are treated end up relapsing, so oncologists need to figure out why they continue to relapse and how does the disease evolve over time. Ultimately, oncologists need to concentrate more on the biology of the disease to better treat patients. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Shaji K. Kumar, MD of Mayo Clinic CHANGE TITLE–Myeloma

Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School explains whether or not somatostatin analogues were needed to see efficacy in treatment for carcinoid syndromes. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School gives an overview of his discussion, Novel Treatment Options for Neuroendocrine Tumors, which was presented at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School discusses the results of the NETTER-1 study, which concluded with patients who were treated with octreotide had significantly improved progression free survival compared to patients who were not treated with the drug. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? explains what to do with patients who have neo-adjuvant chemotherapy and how the response to chemotherapy affects the radiation oncologist’s decision on what should be treated or not. She states that based on the guidelines, the role of radiation is defined by the maximal disease stage. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? stresses the importance of tailoring treatment options to patients’ specific risks. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? discusses the role for regional nodal irradiation in breast cancer treatment. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? gives an overview of the new radiation guidelines for treating patients with breast cancer. She states there are several evolving treatment options and to communicate with patients which options work best for them. She stresses the importance of tailoring those treatment options to the patients’ individual needs and desires. 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? explains how to select effective radiation options for breast cancer treatment. She argues that more treatment is only better if it benefits the patient in the long-run, and ultimately, she is learning that sometimes, more is not always better in select patients. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? gives an overview of her presentation, “Evolving Radiation Therapy Recommendations for Breast Cancer,” which was presented at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Kilian E. Salerno, MD of Roswell Park Cancer Institute? discusses treatment trends in 2017 for breast cancer treatment. She states that many parts of breast cancer management is gravitating towards less radiation and how to use neo-adjuvant chemotherapy to assess next treatments. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group gives an overview of the types of evidence that the National Comprehensive Cancer Network (NCCN) look for when it comes to their guidelines. He states that the NCCN panel is looking for data from not only clinical trials, but other complementary sources of data. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group discusses concerns over patient affordability with cancer care. He argues that the separation between the level of quality in cancer care and what the patient can afford is widening. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group gives an overview of another theme from his session, which was disparities in cancer care. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group gives an overview of the National Comprehensive Cancer Network’s (NCCN) guidelines program and the addition of the evidence blocks. He states that the evidence blocks have an element of affordability, which provides an opportunity for oncologists and other health care professionals to talk with patients about costs. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group discusses themes of his session, which included concerns over cutbacks for the National Institute of Health (NIH). He states that we need continuity in funding of cancer research. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Clifford Goodman, PhD of Lewin Group discusses concerns about a rollback in coverage, losses in preventive services, and affordability in cancer care, which were covered at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute gives an overview of the new staging system by the American Joint Committee on Cancer (AJCC). This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute discusses questions he received from the audience, one being whether or not the staging system is becoming too complicated. He answers yes, it is getting more complicated and more confusing, but at the same time, this will overall improve the value of staging. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute gives an overview of his presentation “Implications of the New AJCC Staging System,” which was presented at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute explains how health care disparities have become a critical issue and an area of discussion at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute discusses the importance of personalized medicine, specifically genomic profiling in breast cancer. He states that with more use in genomic profiling, chemotherapy has decreased in need. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Stephen B. Edge, MD of Roswell Park Cancer Institute discusses the American Joint Committee on Cancer (AJCC) and its collaboration with Union International Cancer Control (UICC) for global use, where patients can be compared across the globe. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lois Ramondetta, MD of MD Anderson Cancer Center gives an overview of her presentation, HPV Vaccine Champion Training for Gynecologic Oncologists, which was presented with Dr. Jennifer Young Pierce of Medical University of South Carolina at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Lois Ramondetta, MD of MD Anderson Cancer Center discusses the importance of communicating the safety and efficacy of the HPV vaccine with other healthcare professionals, primary care physicians, and families. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Lois Ramondetta, MD of MD Anderson Cancer Center gives an overview of an HPV-related abstract that was discussed at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD. She states that the abstract argued the importance of the vaccine in preventing around 6 different types of cancer (vaginal, penile, vulvar, cervical, anal, oropharyngeal).

Jennifer Young Pierce, MD of Medical University of South Carolina gives an overview of her presentation, HPV Vaccine Champion Training for Gynecologic Oncologists, which was presented with Dr. Lois Ramondetta of MD Anderson Cancer Center at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Jennifer Young Pierce, MD of Medical University of South Carolina gives an overview of the practical guidelines for gynecologic oncologists in getting involved with the HPV vaccine outreach. She lists talking with physicians about the vaccine’s role in cancer prevention, introducing survivors, and working with local cancer facilities as just a few approaches. This was recorded at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Jennifer Young Pierce, MD of Medical University of South Carolina discusses the importance of spreading HPV vaccine awareness, especially the data that shows the impact of the vaccine in cancer prevention. This was recorded at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Jennifer Young Pierce, MD of Medical University of South Carolina gives an overview of the treatment trends for the HPV vaccine in 2017. One specific treatment trend is to go from a 3 dose regiment to a 2 dose for regiment for the vaccine, which allows increase completion rates since it can be difficult for patients to come back for the third dose. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center discusses the treatment trends for ovarian cancer for 2017. She highlights the use of FDA-approved PARP inhibitors, immunotherapy, and even combination therapy with PARP inhibitors and immunotherapy. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center explains why it is crucial to use both germline and tumor testing instead of completely skipping germline testing. She states that if clinicians skip the initial germline testing, 10% of BRCA 1 mutations will be missed. This was recorded at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center discusses development of more efficient clinical tests that will accurately predict which patients respond to PARP inhibitors. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Elizabeth Swisher, MD of University of Washington Medical Center gives an overview of a second presentation that discussed the ARIEL2 Trial at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD. From the presentation, the data concluded that the patients who developed platinum-resistance were less likely to respond to the drug. She argues clinicians need to introduce the drug earlier in treatment so patients don’t develop resistance.

Elizabeth Swisher, MD of University of Washington Medical Center discusses her hopes in the ARIEL2 Trial in helping to optimize predictor of response for patients with not only ovarian cancer, but other cancers as well. She states that ovarian cancer is the leading factor in the field of PARP inhibitors and what is learned in ovarian cancer can be applicable to other cancers. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Ruben A. Mesa, MD of Mayo Clinic discusses questions from the audience that were asked during his session on the new guidelines for myeloproliferative neoplasms. He states that overall quality has become the main focus for these guidelines. This was recorded at 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic gives an overview of the upcoming treatment trends for myeloproliferative neoplasms, which include new FDA approved agents, JAK inhibitors, and combination studies. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic gives an overview of interesting topics, such as health disparities and access to care, which were discussed at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic explains the importance of the NCCN and its development of new guidelines for cancer care. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Ruben A. Mesa, MD of Mayo Clinic gives an overview of the new guidelines that are set for leukemia. He states that guidelines ultimately help to identify key areas of unmet needs, specifically drivers in the spectrum of chronic leukemia toward acute leukemia. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Saketh Guntupalli, MD of University of Colorado School of Medicine gives an overview of the kinds of treatment trends for 2017 in his specialty. He states that as a clinician and a surgeon, he hopes to improve the quality of surgeries by finding an easier way to prevent complications, such as blood clots, from happening. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Saketh Guntupalli, MD of University of Colorado School of Medicine explains how patients were picked for his clinical study and their responses to the trial. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Saketh Guntupalli, MD of University of Colorado School of Medicine discusses the importance of his study and how he hopes that the increase of compliance with medication can help prevent blood clots and other bleeding risks in the future. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Saketh Guntupalli, MD of University of Colorado School of Medicine gives his take on how women can deal with their intimate relationships after a cancer diagnosis. He states that this is an area of less interest in cancer survivorship, thus women and clinicians should openly communicate about these kinds of issues. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Saketh Guntupalli, MD of University of Colorado School of Medicine discusses interesting topics that were discussed at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD. He states that there is a new focus on molecular therapeutics in women with cancer, which acts more specifically and effectively in patients.

Saketh Guntupalli, MD of University of Colorado School of Medicine discusses the data of his presentation, which was a randomized trial of oral apixaban and subcutaneous enoxaparin for prevention of blood clots and VTEs in patients with gynecologic malignancies. Data concluded with more risk of bleeding in patients who took a pill than in patients who had blood thinning injections. This was recorded at the Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Thomas Powles, MBBS, MRCP, MD, from the Barts Cancer Institute, London, UK, gives an overview of the KEYNOTE-052 (NCT02335424) trial of pembrolizumab in urothelial bladder cancer at the European Association of Urology (EAU) conference 2017 in London, UK. This Phase II trial is investigating pembrolizumab treatment in urothelial bladder cancer patients ineligible for cisplatin-based chemotherapy. Prof. Powles explains that historically, the majority of patients in this setting have been treated with chemotherapy, and cisplatin is the standard approach in this case, however a substantial proportion of patients are not fit enough or have insufficient renal function for this treatment. Pembrolizumab…

Peter Albers, MD, from the Heinrich-Heine-University Düsseldorf, Germany, discusses the concept of a semi-live surgical masterclass at the European Association of Urology (EAU) conference 2017 in London, UK. He says that this new format has been introduced in surgical education across disciplines over the past few years. Prof. Albers explains that the for a semi-live masterclass, a live surgical procedure is videotaped, and this video is brought to the presentation, and discussed with other presenters, typically comparing different techniques for carrying out a specific procedure, such as anastomosis. An advantage of the semi-live approach is that techniques can be demonstrated…

Maurizio Brausi, MD, from the AUSL Modena, B. Ramazzini Hospital, Modena, Italy, discusses the use of robotic surgery for urological cancers at the European Association of Urology (EAU) conference 2017 in London, UK. He describes the joint session with ERUS, the EAU Robotics section, where kidney, bladder and prostate cancer surgery were debated, comparing open surgery with robotic surgery. Prof. Brausi explains that results are good, both with open and robotic surgery. Taking prostate cancer as an example, oncological results do not differ significantly between the different surgical approaches, however robotics is superior when assessing quality of life, erectile dysfunction…

Jochen Walz, MD, from the Paoli-Calmettes Institute, Marseille, France, discusses the use of magnetic resonance imaging (MRI) in targeting prostate cancer biopsy at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that magnetic resonance imaging (MRI) is currently the most well evaluated tool for prostate cancer diagnosis, and many studies are evaluating this imaging approach. Current recommendations are that an MRI should be carried out before a repeat biopsy, if a suspicion of prostate cancer persists after a negative randomized biopsy. Repeat biopsies identify cancer in 20 25% of cases. By using imaging as additional…

Joaquim Bellmunt, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, discusses recent advances in treating genitourinary malignancies at the European Association of Urology conference 2017 in London, UK. Focusing on immune-oncological agents in bladder cancer, the first-line treatment in patients with metastatic disease is platinum-based chemotherapy, with second-line therapy until recently also being chemotherapy-based, with only vinflunine approved in Europe. In the US, additional second-line agents were used, such as paclitaxel and docetaxel, however limited benefit was seen for patients with these. Recent advances in immune-oncological agents mean that this is now an option for bladder cancer treatment, with…

From our MPN Ask the Expert series, Patient Power viewer, Barb, asks a question about peripheral neuropathy as a side effect of treatment for essential thrombocythemia (ET). Dr. Prithviraj Bose from The University of Texas MD Anderson Cancer Center responds by suggesting treatments that do not cause neuropathy and options for reducing the effects of neuropathy. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Susan C. Modesitt, MD of University of Virginia Health System gives an overview the hot topics and trends that were discussed at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Susan C. Modesitt, MD of University of Virginia Health System discusses the treatment of sentinel lymph nodes, which unintentionally cause isolated tumor cells. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Susan C. Modesitt, MD of University of Virginia Health System explains whether or not hospital readmission is an appropriate marker for quality of life. She argues that it may not be the right metric for success. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Susan C. Modesitt, MD of University of Virginia Health System discusses the use of PARP inhibitors and their benefits towards treating women with ovarian cancer. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC

Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC discusses how the use of PARP Inhibitors work for Ovarian Cancer treatment without BRCA mutations. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC discusses the use of PARP Inhibitors and in combination with Anti-VEGF, Chemotherapy, and Immunotherapy Agents. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC explains why the use of molecular analysis to determine therapy choice is more of a hope to society. He argues that it is not ready for clinical use and discusses the current NCI-MATCH trial. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Alexander B. Olawaiye, MD of Magee-Womens Hospital of UPMC discusses novel agents, Olaparib and Rucaparib, that target BRCA mutations in Ovarian Cancer. He also states that even in patients who did not have any mutation still showed great therapeutic responses from the agents. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Don Dizon, MD of Massachusetts General Hospital discusses data that argued how platinum sensitivity was an important predictor for Rucaparib response. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Don Dizon, MD of Massachusetts General Hospital gives an overview of the treatment trends for 2017 in ovarian cancer treatment, which were discussed at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Don Dizon, MD of Massachusetts General Hospital gives an overview of the SOLO2 Trial and the use of olaparib in ovarian cancer. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Don Dizon, MD of Massachusetts General Hospital discusses the use of novel agents in ovarian cancer. He states that Olaparib and Rucaparib are not FDA approved for clinical trials but are approved for use as a line of treatment for patients who succeeded with chemotherapy but relapsed. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Don Dizon, MD of Massachusetts General Hospital discusses the use of immunotherapy in cervical cancer treatment. He explains a clinical trial where an HPV protein was used for treatment and although there was a low response rate, there was overall improvement of over 50%. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Learn more about personalized medicine, also known as precision medicine, in this web interview with Patient Power Host Andrew Schorr and Dr. Razelle Kurzrock, Director of the Center for Personalized Cancer Therapy at UC San Diego. Dr. Kurzrock explains what needs improvement in cancer therapies, next-generation sequencing, combination therapies, and what patients can do to understand the complex data. Dr. Kurzrock is a pioneer of personalized medicine, and in this replay she goes into detail on how doctors are using advanced technology to look at the combinations of available treatment to see what applies to an individual. Get email alerts…

Christina Annunziata, MD, PhD of National Institutes of Health discusses how some novel agents may meet the guidelines for accelerated approval in phase 2-3 design trials. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Christina Annunziata, MD, PhD of National Institutes of Health explains how the phase 2-3 design decreases the number of patients required to deliver results of clinical trials. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Christina Annunziata, MD, PhD of National Institutes of Health discusses how to take a drug from phase 1 to phase 3. She explains further on how the drug needs to be targeted to the patient with the right marker. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

Christina Annunziata, MD, PhD of National Institutes of Health discusses how future research will be affected by clinical trials. She argues the results of clinical trials will guide future therapy for patients. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.

MPN experts, Dr. Michael Grunwald from Carolinas HealthCare System’s Levine Cancer Institute and Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center, share insights on the purpose of the bone marrow biopsy and how the test affects overall care and treatment decisions. Each expert weighs in on how they monitor patients in their own practice, including why and how frequently their patients are tested. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Philip McCarthy, MD, Director of the Blood and Marrow Transplant Center at Roswell Park Cancer Institute in Buffalo, NY, shares benefits of lenalidomide maintenance therapy for multiple myeloma patients.

Amrita Krishnan, MD FACP Director, Professor of Hematology/Hematopoietic Cell Transplantation gives an update to Multiple Myeloma Research at the MOASC Oncology Summit.

Przemyslaw Twardowski, M.D., Clinical Professor of Medical Oncology, Director, Genitourinary Oncology, City of Hope Cancer Center and David Quinn, MBBS., Ph.D., Section Head, Genitourinary Oncology, Medical Director, USC Norris Cancer Hospital, University of Southern California have a discussion on prostate cancer management at the MOASC Oncology Summit.

Sybil R. Green, JD, RPh, MHA talks about MACRA Rules are Final: Time to Implement the Quality Payment Program at the MOASC Oncology Summit.

James Suh, MD, Senior Pathologist and Associate Medical Director, Laboratory Director, Research Triangle Park, NC discusses the Comprehensive Genomic Profiling: Key Insights for Patient Care at the MOASC Oncology Summit.

At a recent MPN town meeting, Dr. Jigar Trivedi, Clinical Pharmacist Coordinator, Department of Pharmacy at Carolinas HealthCare System’s Levine Cancer Institute, shared insight for patients. Dr. Trivedi discusses dosing and how medications are processed in the body, affecting each person differently. He also explains drug interactions and nurse, Erin Blackwell, stresses the importance of communication with your healthcare team about what youre taking. Watch now to find out how a conversation with a pharmacist can benefit your care. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow…

David Spetzler, PhD, President and Chief Scientific Officer, Caris Life Sciences discusses Caris Molecular Intelligence® Evidence-Guided Molecular Analysis Services at the MOASC Oncology Summit.

Karen Reckamp, MD, Medical Director, Clinical Research, City of Hope Comprehensive Cancer Center discusses The Role of Utilizing Next Generation Sequencing Diagnostics in the Treatment of Lung Cancer at the MOASC Oncology Summit

Edward B. Garon, MD, MS, Director of Thoracic Oncology, David Geffen School of Medicine at UCLA discusses Personalizing lung cancer therapy in the era of next generation sequencing, targeted therapies, and emerging immunotherapies at the MOASC Oncology Summit

In this presentation from Lymphoma & Myeloma 2016, Dr. Robert W. Chen argues in favor of the use of allogeneic stem cell transplant for a Hodgkin lymphoma patents who relapses after autologous stem cell transplant. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Alison Moskowitz argues in favor of the use of serial novel agents (including brentuximab and checkpoint inhibitors) for a Hodgkin lymphoma patents who relapses after autologous stem cell transplant. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Koen van Besien argues for stem cell transplant-based therapy in the treatment of a limited stage Hodgkin lymphoma patient who remains PET positive at the end of chemotherapy. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Ann S. LaCasce argues for radion therapy in the treatment of a limited stage Hodgkin lymphoma patient who remains PET positive at the end of chemotherapy. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Leandro Cerchietti discusses novel therapeutic strategies for B cell lymphomas. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. David Weinstock discusses new targets in peripheral T cell lymphomas. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Steven Treon discusses new insights into the biology and treatment of Waldenström Macroglobulinemia. Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Swaminathan P. Iyer discusses novel agents in the pipleine for the treatment of chronic lymphocytic leukemia (CLL) and lymphoma. Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. John N. Allan provides an update on Richter’s syndrome. Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Neil E. Kay discusses optimal approaches for the management of chronic lymphocytic leukemia (CLL) patients with deletion 17p. Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

Stephen J. Russell, MD, PhD of Mayo Clinic discusses how viral therapy results will trigger a race to complete clinical trials. He states that there has been an increase in clinical trials due to viral therapy emerging as an important combination therapy in immunotherapy. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Stephen J. Russell, MD, PhD of Mayo Clinic explains why viral therapy may prove to be a transformational addition to immuno-oncology. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Stephen J. Russell, MD, PhD of Mayo Clinic explains why recombinant measles and recombinant vesicular stomatitis virus are ideal adjunct to checkpoint immunotherapy. Both have shown impressive activity in pre-clinical models and clinical studies. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute discusses how stress reducing beta blockers combined with immunotherapy may increase response rates in cancer patients. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute explains how patients on beta blockers may do better with immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute gives an overview of her presentation that was presented at ASCO-SITC Symposium. Her presentation focused on mild stress in mouse models, specifically thermal stress, which mirrors stress in humans. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Graham P. Pawelec, PhD of Universitätsklinikum Tübingen explains how new data suggests immunosenescence may not be a factor in immunotherapy treatment. Immunosenescence suggests that older people have an immune system that does not work quite as well as the immune system in younger people. He states that this is a relatively unexplored area in cancer research, but could explain why some patients’ response rates are lower than others. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses the importance of combination strategies in treatment for negative breast cancer. Specifically, in a study that combines pembrolizumab and radiation, it shows great promise for the future of combination therapy in breast cancer. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses the most interesting research she has seen at the ASCO-SITC Symposium. This presentation explained the effects of a microbiome as a predictor of response to checkpoint blockade strategies. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center gives an overview of a poster discussion that was presented at the ASCO-SITC Symposium. This discussion described the results of a randomized study where docetaxel is used with or without plinabulin for patients with non-small cell lung cancer. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses a Phase 1 Study that was being presented at ASCO-SITC. This study combines Carboplatin, Paclitaxel, and an HPV vaccine in the therapeutic setting. She states that even though it is a provocative and early study, the data shows great promise. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Heather McArthur, MD of Cedars-Sinai Medical Center discusses the importance of checkpoint blockade in breast cancer. With the biomarker PDL-1, there has been a 19% response rate in women with triple negative breast cancer. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health discusses promising approaches for looking at tumor microenvironment. He mentions a study that showed patients who received standard of care therapy plus immunotherapy had a better response rate than those who only received standard of care. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health discusses the new research regarding immunotherapies. He states that specifically in colorectal cancer, healthcare professionals are including combinations of vaccines and chemotherapy for treatment. Other treatments include vaccines and checkpoint inhibitors. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health gives an overview of the new and upcoming trends of 2017 for immunotherapy. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering talks about the different types of combinations in immunotherapy. She suggests that two combined treatments are better than one in overcoming resistance. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering advises healthcare professionals to use Nivolumab and Ipilimumab in treating patients with advanced melanoma, especially since there is a 20% response rate. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering discusses the importance of novel combinations for immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Claire Friedman, MD of Memorial-Sloan Kettering discusses the use of combination therapy for patients with melanoma at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Lawrence Fong, MD of University of California, San Francisco discusses the use of more combinations therapies, like Nivolumab and Ipilimumab. This combination therapy is FDA approved for Melanoma, but combination therapies like these may be used for treating new cancers such as Lung, Bladder, and Kidney. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Lawrence Fong, MD of University of California, San Francisco explains how there are several combination therapies to study, but not enough patient-participants for these clinical trials. He hopes for a more rational path regarding patients in order to see which combination therapies will work. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Lawrence Fong, MD of University of California, San Francisco discusses upcoming combination therapies for melanoma treatment that will be FDA approved and used in clinical practice at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego explains how immunotherapy is expanding for cancer treatment into new cancer diseases, especially ones that are more challenging to treat. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego states that in 2017, we will see more combination immuno-therapy for cancer treatment. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego explains how biomarkers and combination therapy may be the path ahead for immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Ezra E.W. Cohen, MD of University of California, San Diego gives an overview of presentations that were discussed at ASCO-SITC. He states that the conference focuses on the new and upcoming research and data in immuno-oncology, such as a new PDL-1, Avelumab. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Stephen M. Ansell, MD, PhD of Mayo Clinic discusses the abstracts and new data that were presented at the second oral session for ASCO-SITC. The research focused on mutations in tumor and how those affects patients’ responses to treatment. This was recorded ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Stephen M. Ansell, MD, PhD of Mayo Clinic discusses the promising and exciting new results from CAR T-Cell data for treatment of not only mesothelioma but other difficult-to-treat diseases. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Keith Argenbright, MD of UT Southwestern Medical Center discusses the geographical barriers for cancer survivorship. In these undeserved areas, which are mostly rural, these patients have circumstances that are hard for most to understand. He hopes that at ASCO, more people will become aware of these barriers. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Keith Argenbright, MD of UT Southwestern Medical Center discusses his presentation “Driving Survivorship Home,” which was presented at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Keith Argenbright, MD of UT Southwestern Medical Center explains how he finds patients for his Mobile Survivorship program. He states that he works with community oncologists, nurse practitioners, and public health clinics for outeach. He hopes to work with anyone who wants to work with them, and that his program will work around the patients’ needs and wants in order for them to have the best outcome. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Keith Argenbright, MD of UT Southwestern Medical Center discusses the advantages of a mobile survivorship program. He states that there are 9 counties in Dallas, Texas where 55% of these areas are “medically underserved,” resulting in the creation of the Mobile Survivorship Program. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses the research he found most intriguing at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses how radiation has changed for invasive bladder cancer treatment. He explains the new and exciting research on biomarkers and its use for figuring out which patients will benefit from radiation therapy of bladder cancer. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses which patients with low-risk prostate cancer should receive radiation. He argues that radiation may not be for every patient and doctors should discuss all the options that are available to their patients. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University explains the difference between the side effects of radiation and surgery/active surveillance and which treatment impacts a prostate cancer patient’s quality of life (QOL). This was recorded at the 2017 Genitourinary (GU) Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University diseases how the use of radiation has been adopted in the treatment for advanced prostate cancer. This was recorded at the 2017 Genitourinary (GU) Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University gives an overview of his presentation “Best of Journals: Prostate Cancer,” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains his perspective on how to integrate drugs into treating patients with metastatic prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains how treatment for prostate cancer has changed since the emerging data on resistance. Based on his knowledge of the disease, he believes that prostate cancer will inevitably evolve to resistance. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains how and when immunotherapy will be used for metastatic prostate cancer treatments at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada discusses how the clinical trials, CHAARTED and STAMPEDE, have impacted his treatment for patients with metastatic hormone sensitive prostate cancer. He states that his patients who received chemotherapy from the study are doing remarkably well and are one step closer to eliminating the entire disease. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada discusses when and where does chemotherapy fit into treatment for prostate cancer. He argues that chemotherapy should be used earlier in the disease. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains why he believes that all metastatic castration-resistant prostate cancer patients should receive chemotherapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida. Who are the right metastatic castration-resistant prostate cancer patients that should be treated with chemotherapy

Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains why BRCA 1 and BRCA 2 genetic testing should be added to the guidelines for treating prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute explains what the biggest challenges are in facing patients and providers in the diagnosis and treatment strategies for patients with metastatic renal cell carcinoma. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute discusses how immunotherapies are being integrated renal cell carcinoma treatment. She states that immunotherapy currently is in second or third line after targeted therapy, but is becoming more of a frontline therapy treatment for kidney cancer. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute explains why chemotherapy has no role for patients with kidney cancer. She argues that targeted therapy and immunotherapy are now mostly used for kidney cancer treatment. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ulka N. Vaishampayan, MD of Karmanos Cancer Institute discusses the research that she thought was most intriguing at Annual Meeting GU. She states that immunotherapy has been the most exciting topic presented. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

At Patient Power’s 2016 town meeting at Levine Cancer Institute in Charlotte, Dr. Srdan Verstovsek explains why MPNs cause night sweats. Dr. Verstovsek discusses the reason symptoms are associated with this systemic disease and how doctors try to counteract those symptoms, including targeting inflammation and cell growth. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Neal D. Shore, MD, FACS of Carolina Urologic Research Center explains how emerging data on resistance has changed treatment for advanced prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Neal D. Shore, MD, FACS of Carolina Urologic Research Center discusses how CHAARTED and STAMPEDE impacted his treatment for patients with metastatic hormone sensitive prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Neal D. Shore, MD, FACS of Carolina Urologic Research Center discusses how and where chemotherapy fits into treating patients with prostate cancer. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Neal D. Shore, MD, FACS of Carolina Urologic Research Center gives his take on which metastatic castration-resistant prostate cancer patients should be treated with chemotherapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Neal D. Shore, MD, FACS of Carolina Urologic Research Center explains how BRCA1 and BRCA2 genetic testing are significantly changing how prostate cancer should be treated. He believes that guidelines are a bit premature, but nonetheless, they are helping with therapy options for patients. This was recorded at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas discusses the medical benefits of finding and nourishing hope, which help patients deal with their uncertainty. She defines hope as a pleasant feeling linked to the belief that the desired outcome can happen. Ultimately, hope is a shared mission, and doctors can help patients by sharing their own hopes for them having the best possible outcome. This was recorded at ASCO’s Cancer Survivorship Symposium: Advancing Care and Research in San Diego, CA.

Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas advises on how to focus on hope for the best clinical outcomes for patients. She believes that hope is a feeling that is based on a belief of a future outcome. Patients are basing their beliefs on what doctors show them, which are stories, impressions, and facts that are based on a reality. If doctors succeed in providing these truths, then hope should naturally occur in patients, and that is the best outcome. This was recorded at ASCO’s Cancer Survivorship Symposium: Advancing Care and Research in San Diego, CA.

Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas explains why there is no one or right approach to survivorship. She states that in order to treat all patients, doctors have to help each patient individually. This was recorded at ASCO’s Cancer Survivorship Symposium: Advancing Care and Research in San Diego, CA.

Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses potential approaches physicians should consider when treating metastatic non-clear cell renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Marcus Butler, MD, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses data on the efficacy of pembrolizumab treatment in advanced mucosal melanoma, which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. This type of melanoma develops for unknown reasons unrelated to UV light exposure, and historically has a lower response rate and overall survival (OS) following various treatments. The development of new melanoma treatments, particularly immunotherapy, led Dr Butler to investigate the efficacy of these in mucosal melanoma by combining the results from the KEYNOTE-001 (NCT01295827), KEYNOTE-002 (NCT01704287), and KEYNOTE-006…

Patrick Miqueu, PhD, from the Jules Bordet Institute in Brussels, Belgium, describes a pilot project to improve the collaboration and communication between cancer patient organizations and hospitals, recorded at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He describes how together with the European Cancer Patient Coalition (ECPC) and Organisation of European Cancer Institutes (OECI), the Jules Bordet Institute aims to develop a minimalist model of fostering collaboration which can be applied in different European countries with existing frameworks. The project focusses on the atmosphere in cancer centers, developing a model which will be…

Lydia Makaroff, PhD, from the European Cancer Patient Coalition, introduces the coalitions new position paper, The Value of Innovation in Oncology, at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. The European Cancer Patient Coalition represents more than 400 cancer patient organizations across Europe. Dr Makaroff describes the new position paper, which contains cost effective and pragmatic recommendations for European institutions and EU member states to ensure cancer patients throughout Europe have access to innovative care, technologies and treatments. The European Cancer Patient Coalition recommends that the assessment of cost effectiveness within Europe should…

Scott Murray, MD, FRCGP, FRCP Edin from the University of Edinburgh, Edinburgh, Scotland, discusses the talk he gave on different features of palliative care at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He highlights three important aspects. Firstly, palliative care needs should be identified as early as possible, starting at diagnosis, and services should be available within the community. Secondly, an assessment of the patients well-being should be made, including not just physical, but also psychosocial, social and existential issues the patient may be experiencing. Thirdly, a plan should be made together with…

Richard Neal, MB, ChB, PhD, FRCGP, from the Leeds Institute of Health Sciences, Leeds, UK, discusses his talk on reducing diagnostic delay for better cancer outcomes, which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He describes that early diagnosis is associated with better cancer outcomes, and suggests that health care systems with a slower diagnosis process can learn from countries with faster diagnosis, resulting in better outcomes. Prof. Neal highlights three ways in which earlier diagnosis can be achieved. Firstly, patients should be encouraged to visit their healthcare practitioner when…

Katsuo Usuda, MD, PhD, from Kanazawa Medical University, Ishikawa, Japan argues that diffusion-weighted magnetic resonance imaging (DWI, MRI) will soon replace PET-CT for lung cancer diagnosis at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He discusses the benefits of diffusion-weighted MRI, which is not only cheaper than PET-CT, but also does not expose the patient to radiation.

Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses how hopeful he is when it comes to treating non-metastatic renal cell carcinoma patients with adjuvant therapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses which non-metastatic renal cell cancer patients should receive adjuvant therapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Matthew I. Milowsky, MD of North Carolina at Chapel Hill School of Medicine discusses how genomics are changing the way bladder cancer subtypes are being treated at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Matthew I. Milowsky, MD of North Carolina at Chapel Hill School of Medicine discusses how genomics are helping us understand heterogeneity in bladder cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Matthew I. Milowsky, MD of University of North Carolina at Chapel Hill School of Medicine discusses his presentation, “Urothelial Carcinoma: Year in Review,” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives his take on the most promising data coming out of the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital discusses presentations he found interesting at the symposium, specifically David J. McConkey’s keynote lecture “Urothelial Carcinoma: Emerging Impact of Genomics on the Clinical Management of Bladder Cancer,” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives an overview of the upcoming treatment trends for genitourinary cancers in 2017, which were discussed at the Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital discusses his presentation, “Orphan Cancers with Opportunities for Improved Treatment (ARS)” and how his data will affect clinicians in the same field at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives an overview of his presentation “Orphan Cancers with Opportunities for Improved Treatment (ARS),” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

James Brugarolas, MD of UT Southwestern Medical Center gives an overview of the new kidney cancer research that was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

James Brugarolas, MD of UT Southwestern Medical Center discusses the use of targeted therapies in treating non-clear cell renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Freddie C. Hamdy, MD of University of Oxford gives an overview of the new research that was discussed regarding prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Freddie C. Hamdy, MD of University of Oxford gives his take on which choice would warrant over the others when it comes to their difference in side effects for patients with metastatic prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Freddie C. Hamdy, MD of University of Oxford discusses the how surgery, radiation, and active surveillance arms of the ProtecT study differ in terms of overall survival and metastasis free patients at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Freddie C. Hamdy, MD of University of Oxford discusses the results of the ProtecT study, which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Freddie C. Hamdy, MD of University of Oxford gives an overview of how the ProtecT study was designed for prostate cancer research at 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses how immunotherapies are being integrated into treatment for renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Eric Jonasch, MD of MD Anderson Cancer Center gives an overview of how targeted therapies are being used in treating non-clear cell renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Eric Jonasch, MD of MD Anderson Cancer Center discusses what approaches should physicians consider when treating patients with metastatic non-clear renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Eric Jonasch, MD of MD Anderson Cancer Center discusses the use of adjuvant therapy to treat patients with non-metastatic renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

James Brugarolas, MD of UT Southwestern Medical Center gives his take on which non-metastatic renal cell cancer patients should receive adjuvant therapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

In this presentation from Lymphoma & Myeloma 2016, Dr. Steven Coutre provides an update on approved tyrosine-kinase inhibitors (TKIs) and their use in clinical practice for the treatment of chronic lymphocytic leukemia (CLL). Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Richard R. Furman discusses the recent FDA approval of venetoclax for the treatment of chronic lymphocytic leukemia (CLL). Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Bruce D. Cheson discusses the role of chemotherapy in the management of chronic lymphocytic leukemia (CLL). Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Susan Slager discusses the epidemiology of chronic lymphocytic leukemia (CLL), and assess what we know about risk. Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Y. Lynn Wang discusses ibrutinib resistance-mechanisms in the treatment of chronic lymphocytic leukemia (CLL). Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Jennifer R. Brown discusses the BCR signaling pathway in the treatment of chronic lymphocytic leukemia (CLL). Click to Earn CME Credit: http://bit.ly/2lDPthL © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Paul G. Richardson examines how to make sense of the many options available for the treatment of relapsed myeloma. Click to Earn CME Credit: http://bit.ly/2mFGsEq © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Tomer M. Mark discusses monoclonal antibodies in the therapeutic treatment of myeloma. Click to Earn CME Credit: http://bit.ly/2mFGsEq © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Adriana C. Rossi discusses whether second- and third-line agents should be used upfront in combination for myeloma patients. Click to Earn CME Credit: http://bit.ly/2mFGsEq © 2016 Imedex, LLC.

This Key Insights activity features conference chair Kathy S. Albain and Dr. Eric P. Winer discussing highlights from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside. Earn CME credit for this activity at the following location: http://elc.imedex.com/ELC/Activity-Overview.aspx?activityid=7244&specialty=Oncology © 2017 Imedex, LLC.

David J. McConkey, PhD of Johns Hopkins Greenberg Bladder Cancer Institute gives his take on what specific drugs have potential in treating bladder cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando Florida.

David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute gives his opinion on what physicians need to know about the progress being made in treating bladder cancer with checkpoint inhibitors at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute discusses whether or not non-invasive imaging will be ready in the future, and what methods should oncologists use to stage and monitor metastatic bladder cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

David J. McConkey of Johns Hopkins Greensberg Bladder Cancer Institute explains why some bladder cancer subtypes respond to immunotherapy and others do not at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute discusses genomics and how they change treatment for bladder cancer subtypes at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

David J. McConkey, PhD of Johns Hopkins Greenberg Bladder Cancer Institute discusses how genomics help our understanding of heterogeneity in bladder cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ana Aparicio, MD of MD Anderson Cancer Center discusses her opinion on whether or not BRCA1 and BRCA2 genetic testing should be added to guidelines for prostate cancer treatment at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ian Tannock, MD, PhD, DSc, from the University of Toronto, Toronto, Canada, discusses the problems limiting the use of personalized medicine at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Personalized medicine is currently typically defined as genetic analysis of a patients tumor, in order to match treatments to the mutations found. Prof. Tannock points out that for some mutations, such as HER2 in breast cancer, matching of treatments to mutations is very successful. However, for many mutations, no effective targeted agents are available. Furthermore, the targeted agents that can be used show similar…

Paolo Ascierto, MD, of the National Tumor Institute Fondazione G. Pascale, Naples, Italy, introduces the SECOMBIT Phase II trial (NCT02631447) in metastatic melanoma with BRAF mutations at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. This trial with around 300 patients will address the important question of which sequence of immunotherapy and targeted therapy is most effective. Prof. Ascierto describes the three-armed SECOMBIT trial, which will compare overall survival (OS) in patients receiving immunotherapy (ipilimumab with nivolumab) followed by targeted therapy (encorafenib with binimetinib), targeted therapy followed by immunotherapy, or the sandwich approach where…

Matti Aapro, MD, from the Clinique de Genolier, Genolier, Switzerland, discusses initiatives such as All.Can, which aim to improve the efficiency of cancer care at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He describes how cancer care can become more sustainable by stopping duplication and follow-ups, which are not clinically useful. Dr Aapro praises the initiatives for considering the views of patients, doctors and nurses, and presenting these to politicians, who can then make well-informed policy decisions.

Markus Hartmann, PhD, from European Consulting & Contracting in Oncology, Trier, Germany, discusses reasons for divergent outcomes of health technology assessment (HTA) and drug pricing across Europe, which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. His study found that while around 80% of European Medicines Agency (EMA) approved medicines were approved by national appraisal bodies in Germany and France, this was only 66% in England (National Institute for Health and Care Excellence, NICE) and 54% in Scotland (Scottish Medicines Consortium, SMC). Dr Hartmann explains the lower approval rates in the…

Laurence Albiges, MD, PhD, from the Gustave Roussy Institute, Villejuif, France discusses the safety of cabozantinib treatment in metastatic renal cell carcinoma at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Cabozantinib is a potent VEGFR tyrosine kinase inhibitor (TKI), and is used for second-line or later treatment in patients in whom prior VEGFR inhibitor treatment failed. Dr Albiges describes common side effects of cabozantinib treatment, which can include hypertension, hand-foot syndrome (acral erythema), diarrhea, and fatigue. Management of these will often require a dose reduction, with 2 out of 3 patients in the…

Ian Tannock, MD, PhD, DSc, from the University of Toronto, Toronto, Canada, gives advice on presenting research at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He points out that poor presentations are often characterized by a lack of planning and no logical sequence, as well as having too many slides or too much information per slide. He suggests a maximum of 10 15 slides for a 10 minute presentation, and highlights that both slides and posters should be easily readable from a distance. Finally, he says that it is also useful to develop…

Francesco Florindi from the European Cancer Patient Coalition introduces new recommendations on fostering collaboration between cancer patient organizations and hospitals, which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He discusses the new guideline document, Solving issues, building relationships, published jointly by the European Cancer Patient Coalition (ECPC), which represents 10 million individuals from over 400 member organizations, and the Organisation of European Cancer Institutes (OECI). Based on frameworks already in place, this document puts together the best practices into a method which member organizations and hospitals can implement to improve…

Paolo Ascierto, MD, of the National Tumor Institute Fondazione G. Pascale, Naples, Italy, gives an overview of the use of biomarkers to select patients for checkpoint inhibitor therapy in melanoma at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He says that there are currently no biomarkers in use to select patients who will benefit from checkpoint inhibitor treatment in melanoma, apart from tumor PD-L1 expression level, which is still controversial in melanoma. However, this is established in other types of cancer, such as the improved response to first-line treatment of metastatic non-small cell…

Matti Aapro, MD, from the Clinique de Genolier, Genolier, Switzerland discusses research on the benefits of pegfilgrastim over filgrastim in managing chemotherapy-induced febrile neutropenia (FN), which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He describes current guidelines stating that there is no difference between the clinical action of the granulocyte colony-stimulating factors (G-CSF) filgrastim and the long-acting pegfilgrastim if given as per label. However, he points out that in practice most health care practitioners prescribe filgrastim by the box, and therefore patients are treated for 5 days instead of the…

Markus Hartmann, PhD, from European Consulting & Contracting in Oncology, Trier, Germany, discusses his talk on divergent outcomes of health technology assessment (HTA) across Europe, which he presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. He explains that while the approval of new drugs is centralized within the European Union at the European Medicines Agency (EMA), the subsequent HTA appraisal process is carried out nationally, with different procedures and different outcomes in various EU member states. The EMA assesses quality, safety and clinical efficacy of the drug, while HTA determines the cost…

Laurence Albiges, MD, PhD, from the Gustave Roussy Institute, Villejuif, France discusses data on the efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma, which she presented at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. She describes that currently, patients typically receive first-line treatment with sunitinib or pazopanib, followed by second-line treatment with nivolumab or the VEGFR inhibitor cabozantinib. However, little is known about the efficacy of cabozantinib and other VEGFR tyrosine kinase inhibitors (TKI) after nivolumab treatment. Dr Albiges speaks about two retrospective data sets, which indicate that VEGFR…

Minh-Ha Tran, DO, Associate Medical Director, Transfusion Medicine, Pathology School of Medicine discusses Adhesion molecules and the role of Rivipansel in sickle cell at MOASC Spotlight on ASH meeting 2017.

Minh-Ha Tran, DO, Associate Medical Director, Transfusion Medicine, Pathology School of Medicine discusses Daratumumab could result in false positive reactivity for antibody testing in multiple myeloma at MOASC Spotlight on ASH meeting 2017.

Deepa Jeyakumar, MD, Assistant Clinical Professor, Division of Hematology/Oncology, UC Irvine Health discusses New Clinical Impacts on AML for 2017 at MOASC Spotlight on ASH meeting 2017.

Deepa Jeyakumar, MD, Assistant Clinical Professor, Division of Hematology/Oncology, UC Irvine Health discusses AML Highlights from ASH 2016 at MOASC Spotlight on ASH meeting 2017.

Lauren C. Pinter-Brown MD, FACP, Health Sciences Professor of Medicine and Dermatology, Chao Family Comprehensive Cancer Center, UC-Irvine discusses the Potential Impact of CAR T Cell Therpy in Lymphoma at the MOASC Spotlight on ASH meeting 2017

Lauren C. Pinter-Brown MD, FACP, Health Sciences Professor of Medicine and Dermatology, Chao Family Comprehensive Cancer Center, UC-Irvine discusses practice changing data from ASH 2016 in Lymphoma at the MOASC Spotlight on ASH meeting 2017

Lauren C. Pinter-Brown MD, FACP, Health Sciences Professor of Medicine and Dermatology, Chao Family Comprehensive Cancer Center, UC-Irvine compares Obinutuzumab vs. rituximab with chemotherapy in follicular lymphoma at the MOASC Spotlight on ASH meeting 2017

Gordon D. McLaren, M.D., University of California, Irvine, Irvine, CA, VA Long Beach Healthcare System, Long Beach, CA discusses how phlebotomy for hemochromatosis still best practice at the MOASC Spotlight on ASH 2017.

Gordon D. McLaren, M.D., University of California, Irvine, Irvine, CA, VA Long Beach Healthcare System, Long Beach, CA discusses the Wider testing needed to determine iron-overload phenotype at the MOASC Spotlight on ASH 2017.

Gordon D. McLaren, M.D., University of California, Irvine, Irvine, CA, VA Long Beach Healthcare System, Long Beach, CA discusses the Identification of New BMP6 Pro-Peptide Mutations in Patients with Unexplained Iron-Overload at the MOASC Spotlight on ASH 2017.

Yasir Khan, MD, UC Irvine Health outlines how early studies show that DOACS may be promising in VTE at the MOASC Spotlight on ASH 2017.

Yasir Khan, MD, UC Irvine Health, compares Low Molecular Weight Heparin vs. DOACS in the management of DVT and VTE at the MOASC Spotlight on ASH 2017.

Yasir Khan, MD, UC Irvine Health, outlines how DOACS studies may be practice changing for VTE at the MOASC Spotlight on ASH 2017 meeting.

Angela Fleischman MD PhD, UC Irvine Health discusses how a Trametinib Early Study Shows Impressive Results for MPN at MOASC Spotlight on ASH 2017.

Angela Fleischman MD PhD, UC Irvine Health outlines the real world changes in MPN for 2017 at the MOASC Spotlight on ASH 2017 meeting.

Angela Fleischman MD PhD, UC Irvine Health discusses the new developments in MPN for 2017 at the MOASC Spotlight on ASH 2017.

Aditi Choudhry, MD, Hematology Oncology Fellow UC Irvine discusses how Ibrutinib May Replace Chemotherapy in CLL at MOASC Spotlight on ASH 2017 meeting.

Aditi Choudhry, MD, Hematology Oncology Fellow UC Irvine discusses the 5 Year Experience With Ibrutinib in CLL at the MOASC Spotlight on ASH 2017.

Elizabeth Brém, MD, HS Clinical Assistant, Professor Chao Comprehensive Cancer Center discusses the Future of Relapse Refractory Treatment in Hodgkins Lymphoma at the MOASC Spotlight on ASH meeting 2017.

Elizabeth Brém, MD, HS Clinical Assistant Professor, Chao Comprehensive Cancer Center discussing Incorporating immunotherapy in Hodgkins Lymphoma at the MOASC Spotlight on ASH meeting 2017.

Elizabeth Brém, MD, HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Using PET Scan for Early Stage Hodgkin Lymphoma at MOASC Spotlight on ASH meeting 2017.

Ana Aparicio, MD of MD Anderson Cancer Center discusses her presentation “Advances in the Understanding and Treatment of AR-Indifferent Disease,” which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ana Aparicio, MD of MD Anderson Cancer Center gives her perspective on how to sequence commonly used agents in prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ana Aparicio, MD of MD Anderson Cancer Center gives her take on whether immunotherapy will be added to treatment guidelines for prostate cancer in the near future at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ana Aparicio, MD of MD Anderson Cancer Center discusses how the CHARTED and STAMPEDE trials impacted her treatment for patients with metastatic hormone sensitive prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ana Aparicio, MD of MD Anderson Cancer Center discusses how and where does chemotherapy fit for treating patients with prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Ana Aparicio, MD of MD Anderson Cancer Center gives her take on which prostate cancer patients should be treated with chemotherapy at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Aly-Khan Lalani, MD of Dana Farber Cancer Institute gives an overview of his poster presentation about proton pump inhibitors in renal cell carcinoma, which was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Aly-Khan Lalani, MD of Dana Farber Cancer Institute gives his thoughts on the use of immunotherapy to treat patients with renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Aly-Khan Lalani, MD of Dana Farber Cancer Institute discusses the integration of immunotherapies into renal cell carcinoma at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Aly-Khan Lalani, MD of Dana Farber Cancer Institute gives an overview of the research he found most interesting, which were presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Alexandra Drakaki, MD, PhD of University of California, Los Angeles gives an overview of the highlights in Bladder Cancer research that was presented at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Alexandra Drakaki, MD, PhD of University of California, Los Angeles discusses what physicians need to know about the progress that’s being made with checkpoint inhibitors for treatment of Bladder Cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Alexandra Drakaki, MD, PhD of University of California, Los Angeles discusses the role of microRNA in Bladder Cancer and its clinical implications at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.

Georgina Long, MD, PhD, from the University of Sydney, Sydney, Australia, gives an overview of her talk on neoadjuvant therapy in bulky Stage III melanoma at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. She discusses a trial (NCT01972347) using drugs effective in advanced melanoma at an earlier stage, whose results show that 50% of patients with bulky Stage III melanoma who received neoadjuvant treatment with dabrafenib and trametinib showed a complete pathologic response (cPR) following tumor resection, with the effect of this on long-term outcome still being assessed. Prof. Long highlights the importance…

Martin Gore, PhD, FRCP, CBE from the Royal Marsden NHS Foundation, London, UK discusses why inefficiency in cancer care should be addressed at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Prof. Gore highlights that inefficient cancer care, such as long waiting times and repeated tests, not only lead to financial losses, but also negatively impacts the patient experience by taking up large amounts of patient time, and not just that of health care professionals. He argues that this can best be addressed by taking action guided by patient surveys, rather than just being…

Rodabe N. Amaria, MD from the University of Texas MD Anderson Cancer Center, Houston, TX gives an overview on the benefits of combined treatment with BRAF and MEK inhibitors for metastatic melanoma at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. She discusses the benefits of targeted therapy for melanoma with BRAF mutations using a combination of BRAF and MEK inhibitors, which are FDA-approved for Stage IV metastatic melanoma. Treatment with a single agent has a limited efficacy of 6-7 months before disease recurrence, as well as being less well tolerated. However, Dr Amaria…

Susan OBrien, M.D., UC Irvine Health outlines how small molecule combinations may some day supplant chemotherapy in CLL at MOASC Spotlight on ASH 2017.

Susan OBrien, M.D., UC Irvine Health gives an Update on Resonate 2 Trial and presents new Venetoclax data at MOASC Spotlight on ASH 2017.

Susan OBrien, M.D., UC Irvine Health discusses how new Ibrutinib data may change current practices in CLL from MOASC Spotlight on ASH 2017

Minh-Ha Tran, DO, Associate Medical Director, Transfusion Medicine, Pathology School of Medicine presents an updates in transfusion medicine at the MOASC Spotlight on ASH